22 peptides tracked
Australia's
Independent
Peptide Register
No vendors. No affiliates. Just data.
Fig. 01
Regulatory Status · May 2026
Retatrutide2
GHK-Cu10
Semaglutide12
Tirzepatide8
BPC-15718
CJC-129515
22
Peptides tracked
40
Prescription providers
52
Observed suppliers
1
Prohibited (S9)
01Intelligence
Peptide Status
TGA scheduling, enforcement trends, and access pathways for each peptide. Updated June 2026.
Editorial position: We recommend accessing peptides through an AHPRA-registered medical practitioner and TGA-licensed compounding pharmacy. This ensures clinical oversight, pharmaceutical-grade compounding, and legal compliance.
Retatrutide
Triple Agonist (GLP-1/GIP/Glucagon)
GHK-Cu
Copper Peptide
Semaglutide
GLP-1 Agonist
Tirzepatide
GLP-1/GIP Agonist
BPC-157
Tissue Repair
CJC-1295
Growth Hormone Secretagogue
Ipamorelin
Growth Hormone Secretagogue
TB-500
Tissue Repair
Melanotan II
Melanocortin Agonist
PT-141 (Bremelanotide)
Melanocortin Agonist
MOTS-c
Mitochondrial Peptide
Thymosin Alpha-1
Immune Modulator
KPV
Anti-inflammatory Peptide
Epithalon
Telomerase Activator
Gonadorelin
Hormonal Support
Dihexa
Cognitive Enhancement
02News
Regulatory Feed
Latest scheduling changes, enforcement actions, and market developments across all tracked peptides.
HeadlineSourceDate
Acute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague-Dawley rats.Semaglutide
Behavioural pharmacology2 June 202615-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss.Semaglutide
Proceedings of the National Academy of Sciences of the United States of America2 June 2026Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.Semaglutide
PharmacoEconomics2 June 2026Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.Tirzepatide
Endocrinol Diabetes Metab1 June 2026Semaglutide in metabolic dysfunction-associated alcohol-related liver disease: a potential dual-target therapy for metabolic dysfunction and alcohol use.Semaglutide
Eur J Gastroenterol Hepatol1 June 2026GIPR:GCGR co-agonism restores normal weight in obese rodentsRetatrutide
Mol Metab1 June 2026[Advances in Anti-Dementia Therapies in Older Adults].Semaglutide
Dtsch Med Wochenschr1 June 2026DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model.Tirzepatide
Mol Ther Nucleic Acids1 June 2026Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies.Tirzepatide
Dermatol Surg1 June 2026The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms.Tirzepatide
Dermatol Surg1 June 2026GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.Semaglutide
Dermatol Surg1 June 2026A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of RetatrutideRetatrutide
Org Lett1 June 2026Do GLP-1 Receptor Agonists Sabotage Fat Grafts? : A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat TransferRetatrutide
Aesthet Surg J1 June 2026Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cellsKPV
Cytotechnology1 June 2026Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Semaglutide
Clinical pharmacokinetics1 June 2026Tirzepatide-Associated Lithium Toxicity Necessitating Hemodialysis in Previously Stable Bipolar I Disorder.Tirzepatide
Journal of clinical psychopharmacology1 June 2026Eating Disorders in the GLP-1 Era: A Spotlight on Emerging Clinical Risks, Research Gaps, and Practice Priorities.Tirzepatide
The International journal of eating disorders1 June 2026Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation.BPC-157
Integrative medicine (Encinitas, Calif.)1 June 2026Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney diseaseRetatrutide
Nephrol Dial Transplant29 May 2026After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 CareSemaglutide
J Med Internet Res28 May 2026Regulatory Notice
For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.